Newsfeeds - Spark Newswire

1 minute read

The FDA has Cleared Vertex Pharmaceuticals’ Investigational New Drug Application For VX-264, Stem Cell-Derived Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into Vertex-Developed, Immunoprotective Device For Type 1 Diabetes

Today, 3:18 PM

Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023 to study the safety, tolerability and efficacy of VX-264 in patients with T1D. The company previously received approval from Health Canada

VRTX

2 minute read

(VRTX) – Analyzing Vertex Pharmaceuticals’s Short Interest

By Benzinga Insights

Today, 3:18 PM

Vertex Pharmaceuticals’s (NASDAQ:VRTX) short percent of float has fallen 11.38% since its last report. The company recently reported…

VRTX

1 minute read

News

ImmunoGen Enters Multi-Target License & Option Agreement With Vertex; To Receive $15M Upfront & Up To $337M Milestone Payments

By Benzinga Newsdesk

Today, 3:18 PM

As part of the agreement, Vertex will pay ImmunoGen an upfront payment of $15 million. ImmunoGen is eligible to receive up to $337 million in option exercise fees and development and commercial milestone

IMGN

2 minute read

Robinhood, Merck And 2 Other Stocks Insiders Are Selling

By Lisa Levin

Today, 3:18 PM

The Nasdaq closed higher by around 0.6% on Tuesday, also recording losses for the week. Investors, meanwhile, focused on some notable insider trades.

HOOD

2 minute read

What’s Going On With Vertex Pharmaceuticals (VRTX) Stock Wednesday?

By Henry Khederian

Today, 3:18 PM

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are trading lower by 1.44% to $304.10 Wednesday morning. The company on Tuesday reported fourth-quarter financial results. What Happened?

VRTX

1 minute read

Why Vertex Pharmaceuticals Stock Is Moving During Tuesday’s After-Hours Session

By Henry Khederian

Today, 3:18 PM

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading marginally lower by 0.82% to $306 during Tuesday's after-hours session.

VRTX

9 minute read

Earnings

Earnings Scheduled For February 7, 2023

By Benzinga Insights

Today, 3:18 PM

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

AAT

1 minute read

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $286

By Benzinga Newsdesk

Today, 3:18 PM

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and raises the price target from $285 to $286.

VRTX